Finally, FASN inhibition negatively regulates cytosolic phospholipase A2 (PLA2G4A) and estradiol 17‐beta‐dehydrogenase 12 (HSD17B12) in several prostate cancer cell lines. Here, FASN is linked to prostate carcinoma.